PHAT News and Press, Phathom Pharmaceuticals Inc. From 04/01/22

FLORHAM PARK, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team ...

Phathom Pharmaceuticals (NASDAQ:PHAT) stated Tuesday that it has appointed Molly Henderson as the company's new chief financial and business officer, effective Apr. 5, 2022. Henderson has most recently served as CFO of UroGen Pharma (URGN), and previously at Advaxis (OTC:ADXS)....

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson t...

FLORHAM PARK, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has submitted a new drug app...

Phathom Pharmaceuticals press release (NASDAQ:PHAT): Q4 GAAP EPS of -$0.95 beats by $0.05. As of December 31, 2021, cash and cash equivalents were $183.3 million. Cash and cash equivalents combined with the future drawdown of the remaining $100 million under our loan agreement are expected to...

FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quar...

Announcing topline data from its PHALCON-NERD trial for vonoprazan, Phathom Pharmaceuticals (NASDAQ:PHAT) said that the experimental on-demand therapy for episodic heartburn met the main goal in subjects with non-erosive gastroesophageal reflux disease (NERD). In reaction, Phathom (PHAT) shar...

Vonoprazan met the primary endpoint for all three dose levels (10 mg, 20 mg, 40 mg) taken on-demand, demonstrating faster and sustained relief of episodic heartburn as compared to placebo (p<0.0001) Phathom has commenced a Phase 3 NERD development program with the initiat...

FLORHAM PARK, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team w...

FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team w...